Cassava Sciences Shares Lower Premarket on $40M Penalty to Settle Doctored Data Claims
The SEC also said Dr. Hoau-Yan Wang, a Cassava consultant, was charged with manipulating the reported clinical trial results. Without admitting or denying the violations, Wang agreed to cease and desist from future violations and to pay a monetary penalty, the SEC said.
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...
MeridianLink announced an underwritten secondary public offering of 6 million shares by funds managed by Thoma Bravo. The selling stockholders plan to grant the underwriter an option to purchase up to ...
Following our analysis of the options activities associated with Cassava Sciences, we pivot to a closer look at the company's ...
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials ...
Discover how Cassava Sciences Inc. secures a patent for innovative pharmaceutical compositions using crystalline and amorphous polymorphs, enhancing therapeutic efficacy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback